The drug indication, that Eaton Scientific named Tropine 3, is currently being prescribed and compounded by doctors in the Los Angeles, California specifically for their patients who have hot flash symptoms and do not want to take hormonal treatment.
Tropine 3 has been shown in individual cases to reduce the symptoms of hot flashes in terms of intensity, duration, and number of occurrences without the use of dangerous hormones which," said Michael Borkowski, CEO and President of Eaton Scientific Systems, Ltd.
holds the intellectual property and global marketing rights to Tropine
3, a patent pending novel indication of an existing FDA approved drug for the non-hormonal treatment of hot flashes in pre-menopausal, peri-menopausal, and post-menopausal women.
With this in mind, we intend to develop Tropine 3 to take advantage of potential global marketing and distribution opportunities.
The earlier onset of menopause and increased prevalence of menopause symptoms outside of North America represents an important strategic opportunity to expand Tropine 3 awareness on a global scale.
As a result, novel non-hormonal treatments such as Tropine
3 are poised to overtake traditional hot flash treatments.
Berman has also agreed to be an advocate of Tropine
3, and to organize and participate in select media interviews and other public relations opportunities (television, radio, print, etc.
OTCQB: PRTN) is pleased to announce that it has completed the Protocol for the Clinical Trial for Tropine
3, its novel indication of homatropine, in oral suspension to be prescribed to women afflicted with hot flashes during pre-menopause, peri-menopause, and post-menopause.
Hootan Melamed, whose family's Beverly Hills, CA based Rox San Pharmacy is the original compounding Pharmacy for Tropine
3, a Novel indication of Homatropine in oral suspension.
CEO, Michael Borkowski, says that "the Million Women Study, is both alarming and important to the need for non-hormonal treatments like Eaton's Tropine
3 in dealing with pre-menopause, menopause and peri-menopause symptoms affecting millions of women in the US and around the world who do not want to risk using hormonal treatments because of their potential relationship with cancer.
CCRA, to develop and oversee FDA compliant trials of Tropine
3 for non-hormonal treatment of hot flashes in menopausal women.
OTCQB: PRTN) is pleased to announce select details of its planned multi-phase multi-location clinic trials for FDA approval of its novel drug indication Tropine
3, containing currently FDA approved Homatropine, in oral an suspension.